Jane Street
GALT icon

Jane Street’s Galectin Therapeutics GALT Stock Holding History

Jane Street’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70,100
Closed -$90.4K – 9809
2024
Q4 		$90.4K Buy
+70,100
New +$168K ﹤0.01% 8793

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Jane Street's GALT Position: Q1 2026 in Review

Jane Street reduced its Galectin Therapeutics (GALT) stake by 2.2% in Q1 2026, selling an estimated $13.6K and leaving 194,868 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #7848.

Jane Street first reported a position in GALT in Q3 2013 and has held it in 15 quarters since. The position peaked at $1.58M in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Jane Street held 194,868 shares of Galectin Therapeutics worth $544K as of Q1 2026.
  • Jane Street sold 4,471 Galectin Therapeutics shares in Q1 2026, an estimated $13.6K.
  • Galectin Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7848 holding.
  • Jane Street first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 15 quarters since.
  • Jane Street's Galectin Therapeutics position peaked at $1.58M in Q2 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.